Yi-Hsuan Tu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yi-Hsuan Tu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Anisha M. Patel
Genentech, Inc., South San Francisco, CA USA
1 shared publication Deliang Tang
Department of Environmental Health Sciences, Columbia Center for Children's Environmental Health, Mailman School of Public Health of Columbia University, New York, New York and
1 shared publication- Douglas A. Bell
Immunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 27709, USA.
1 shared publication - Frederica P. Perera
Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, USA; Columbia Center for Children's Environmental Health, Columbia University, New York, NY, USA
1 shared publication Ivona Bendkowska
Department of Environmental Health Sciences, Columbia Center for Children's Environmental Health, Mailman School of Public Health of Columbia University, New York, New York and
1 shared publicationKarina Raimundo
1 shared publication
Latest Publications
- Open Access
- 6 July 2024
- Published by Elsevier in CHEST Pulmonary
- Vol. 2 (4)
Impact of Pirfenidone on Patient-Reported Outcomes in Patients With Idiopathic Pulmonary Fibrosis From the Pulmonary Fibrosis Foundation Patient Registry
- 6 July 2024
- Published by Elsevier in CHEST Pulmonary
- Vol. 2 (4)
Open AccessImpact of Pirfenidone on Patient-Reported Outcomes in Patients With Idiopathic Pulmonary Fibrosis From the Pulmonary Fibrosis Foundation Patient Registry
- Open Access
- 1 July 2006
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 15 (7) , 1417-1419
Lack of Associations among Cancer and Albumin Adducts, ras p21 Oncoprotein Levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in a Nested Case-Control Study of Lung Cancer within the Physicians' Health Study
There was a priori evidence that PAH-albumin adducts and ras p21 of the biomarkers were biologically relevant, but their predictive ability had not been evaluated in a prospective design. For example, studies have shown that certain protein adducts, including PAH-albumin adducts, are correlated with the corresponding DNA adducts and might serve as feasible surrogates (2). However, the half-lives of the two biomarkers vary, and, unlike DNA adducts, protein adducts do not reflect interindividual variability in DNA repair. The ras oncogene has been shown to be activated by mutagens and clastogens. Moreover, ras mutation and/or overexpression has been directly implicated in the development of lung tumors (3-9). We also examined the contribution of polymorphisms in genes controlling metabolic activation and detoxification pathways for carcinogens that mediate the initial steps in environmental carcinogenesis (10). Genetic polymorphisms in the selected genes have been previously implicated in at least one study of lung cancer, although results have not been consistent (11-13).
- 1 July 2006
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 15 (7) , 1417-1419
Open AccessLack of Associations among Cancer and Albumin Adducts, ras p21 Oncoprotein Levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in a Nested Case-Control Study of Lung Cancer within the Physicians' Health Study
There was a priori evidence that PAH-albumin adducts and ras p21 of the biomarkers were biologically relevant, but their predictive ability had not been evaluated in a prospective design. For example, studies have shown that certain protein adducts, including PAH-albumin adducts, are correlated with the corresponding DNA adducts and might serve as feasible surrogates (2). However, the half-lives of the two biomarkers vary, and, unlike DNA adducts, protein adducts do not reflect interindividual variability in DNA repair. The ras oncogene has been shown to be activated by mutagens and clastogens. Moreover, ras mutation and/or overexpression has been directly implicated in the development of lung tumors (3-9). We also examined the contribution of polymorphisms in genes controlling metabolic activation and detoxification pathways for carcinogens that mediate the initial steps in environmental carcinogenesis (10). Genetic polymorphisms in the selected genes have been previously implicated in at least one study of lung cancer, although results have not been consistent (11-13).